image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Latest issue now available

Babcock - Interim results beat expectations

January 2023

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • BAB
  • Price:
  • 290p
In spite of share price weakness, defence contractor Babcock pleased investors with interim results to 30 September ahead of expectations with EBIT and eps ahead of forecasts at £121.7m and 15.8p. More dramatic still was that net debt to EBITDA fell to 1.9x (H1 ‘22: 2.8x) thanks to strong free cash flow while there’s no requirement for refinancing until 2026 after a €550m Eurobond was repaid last month. 85% of its debt is on fixed rates, up from 70%. Babcock maintained a strong contract backlog at £9.9 billion providing cover of 90% FY23 expected revenue. With guidance unchanged JP Morgan Cazenove expects eps of 33.8p year to March, rising to 40.4p in ‘24, for a prospective PE of 8.6 and then 7.2. Its price target is 475p. ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Related Articles

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

author